The challenges of developing an API crystallization process for a complex polymorphic and highly solvating system. Part I

Organic Process Research and Development

Volumn 13, Issue 6, 2009, Pages 1327-1337

  Chekal, Brian P ^a   Campeta, Anthony M ^a   Abramov, Yuriy A ^a   Feeder, Neil ^b   Glynn, Paul P ^b   McLaughlin, Robert W ^a   Meenan, Paul A ^a   Singer, Robert A ^a  

^a PFIZER INC   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 72449136683     PISSN: 10836160     EISSN: 1520586X     Source Type: Journal    
DOI: 10.1021/op9001559     Document Type: Article

References (39)

1. Woodcock, J. Am. Pharm. Rev. 2004, (Nov.-Dec.), 1.
2. Bernstein, J. Polymorphism in Molecular Crystals; Clarendon: Oxford, 2002.
3. Hilfiker, R. Polymorphism in the Pharmaceutical Industry; Wiley-VCH: New York, 2006.
4. Brittain, H. Polymorphism in Pharmaceutical Solids; Marcel Dekker Inc: New York, 1999.
5. Byrn, S. Solid State Chemistry of Drugs; SSCI Inc: West Lafayette, IN, 1999.
6. Chemburkar, S. R.; Bauer, J.; Deming, K.; Spiwek, H.; Patel, K.; Morris, J.; Henry, R.; Spanton, S.; Dziki, W.; Porter, W.; Quick, J.; Bauer, P.; Donaubauer, J.; Narayanan, B. A.; Soldani, M.; Riley, D.; McFarland, K. Org. Process Res. Dev. 2000, 4, 413.
7. Bauer, J.; Spanton, S.; Henry, R.; Quick, J.; Dziki, W.; Porter, W.; Morris, J. Pharm. Res. 2001, 18 (6), 859.
8. Desikan, S.; Parsons, R. L.; Davis, W. P.; Ward, J. E.; Marshall, W. J.; Toma, P. H. Org. Process Res. Dev. 2005, 9, 933.
9. Rouhi, A. M. Chem. Eng. News 2003, 81 (8), 32.
10. Goho, A. Sci. News Online 2004, 166, 122.
11. Almarrson, O.; Hickey, M. B.; Peterson, M. L.; Morissette, S. L.; Soukasene, S.; McNulty, C.; Tawa, M.; MacPhee, J. M.; Remena, J. F. Cryst. Growth Des. 2003, 3, 927.
12. Hilfiker, R.; Berghausen, J.; Blatter, F.; Burkhard, A.; De Paul, S. M.; Freiermuth, B.; Geoffroy, A.; Hofmeier, U.; Marcolli, C.; Siebenhaar, B.; Szelagiewicz, M.; Vit, A.; von Raumer, M. J. Therm. Anal. Calorim. 2003, 73, 429.
13. Storey, R.; Docherty, R.; Higginson, P.; Dallman, C.; Gilmore, C.; Barr, G.; Dong, W. Crystallogr. Rev. 2004, 10 (1), 45.
14. Day, G. M.; Motherwell, W. D. S.; Ammon, H. L.; Boerrigter, S. X. M.; Della Valle, R. G.; Venuti, E.; Dzyabchenko, A.; Dunitz, J. D.; Schweizer, B.; van Eijck, B. P.; Erk, P.; Facelli, J. C.; Bazterra, V. E.; Ferraro, M. B.; Hofmann, D. W. M.; Leusen, F. J. J.; Liang, C.; Pantelides, C. C.; Karamertzanis, P. G.; Price, S. L.; Lewis, T. C.; Nowell, H.; Torrisi, A.; Scheraga, H. A.; Arnautova, Y. A.; Schmidt, M. U.; Verwer, P. Acta Crystallogr. 2005, B61, 511.
15. Day, G. M.; Motherwell, W. D. S.; Jones, W. Phys. Chem. Chem. Phys. 2007, 9, 1693.
16. Price, S. L. Int. Rev. Phys. Chem. 2008, 27 (3), 541.
17. Galek, P. T. A.; Fabian, L.; Motherwell, W. D. S.; Allen, F. H.; Feeder, N. Acta Crystallogr., Sect. B 2007, 63, 768.
18. Hu-Lowe, D. D.; Zou, H. Y.; Grazzini, M. L.; Hallin, M. E.; Wickman, G. R.; Amundson, K.; Chen, J. H.; Rewolinski, D. A.; Yamazaki, S.; Wu, E. Y.; McTigue, M. A.; Murray, B. W.; Kania, R. S.; O'Connor, P.; Shalinsky, D. R.; Bender, S. L. Clin. Cancer Res. 2008, 14, 7272.
19. Ye, Q.; Hart, R. M.; Kania, R.; Ouellette, M.; Wu, Z. P.; Zook, S. E. Polymorphic Forms of 6-[2-Methylcarbomoyl)phenylsulfanyl]-3-E-[2-pyridin-2-yl) ethenyl]indazole, U.S. Patent 0094763, 2006.
20. Quallich, G. In Early Clinical Drug Development: From Synthesis Design to Formulation, Abdel-Magid, A. Caron, S., Eds.; John Wiley and Sons: New York, 2006.
21. Mullin, J. W. Crystallization, 4th ed.; Butterworth-Heinemann: Oxford, 2001; Sect. 1.8, pp 16-18.
22. Flahive, E. J.; Ewanicki, B. L.; Sach, N. W.; O'Neill-Slawecki, S. A.; Stankovic, N. S.; Yu, S.; Guinness, S. M.; Dunn, J. Org. Process Res. Dev. 2008, 12, 637.
23. Stahl, P. H.; Wermuth, C. G. Handbook of Pharmaceutical Salts, Properties, Selection and Use; VHCA and Wiley-VCH: Zurich and Weinheim, 2002.
24. Black, S. N.; Phillips, A.; Scott, C. I. Org. Process Res. Dev. 2009, 13, 78.
25. This process could have been made more robust via the use of Form IV seed as it would avoid the effects of inconsistent generation of Form IV. For a review of seeding to control polymorphism, see: Beckman, W. Org. Process Res. Dev. 2000, 4, 372.
26. Burger, A.; Ramberger, R. Mikrochim. Acta II 1979, 259.
27. James, K. C. Solubility and Related Properties; Marcel Dekker: New York and Basel, 1986.
28. Mullin, J. W. Crystallization, 4th ed.; Butterworth-Heinemann: Oxford, 2001; Sect. 5.4, pp 205-206.
29. Ostwald, W. Z. Phys. Chem. 1897, 22, 289.
30. The addition of seed crystals of the desired form (Form XXV) would have resulted in a more robust process for completing this polymorph conversion.
31. Dunitz, J.; Bernstein, J. Acc. Chem. Res. 1995, 28, 193.
32. Subsequent solubility studies that incorporated on-line Raman spectroscopy to monitor the solid form indicated that Form XXV had a lower solubility than the ethanol solvate forms (Form XII or Form XV) of axitinib in ethanol at temperatures above 25 °C.
33. Klamt, A. COSMO-RS: From Quantum Chemistry to Fluid-Phase Thermodynamics and Drug Design; Elsevier: Amsterdam, 2005.
34. TURBOMOLE, Version 5.10; Program Package for ab Initio Electronic Structure Calculations; Cosmologic GmbH: Leverkusen, Germany, 2008.
35. Becke, A. D. Phys. Rev. A 1988, 38, 3098.
36. Perdew, J. P. Phys. Rev. B 1986, 33, 8822.
37. Eckert, F.; Klamt, A. COSMOTherm, Version C2.1, Revision 01.07; COSMOLogic GmbH: Leverkusen, Germany, 2007.
38. Burger, A.; Ramberger, R. Mikrochim. Acta II 1979, 273.
39. Campeta, A. M.; Chekal, B. P.; McLaughlin, R. W.; Singer, R. A. (Pfizer Products Inc., U.S.A.). Novel Crystalline Forms of a VEGF-r Inhibitor PCT Int. Appl. WO 2008122858, 2008.